Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder

Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder

"Purpose: Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek®) in adults diagnosed with OAB through a multicenter, prospective, non-inter...

Full description

Bibliographic Details
Main Authors: Jee Soo Park, Won Sik Jang, Jongchan Kim, Moon-Hwa Park, Won Sik Ham
Format: Article
Language:English
Published: Korean Urological Association 2025-01-01
Series:Investigative and Clinical Urology
Subjects:
adrenergic beta-3 receptor agonists
mirabegron
urinary bladder
overactive
Online Access:https://www.icurology.org/pdf/10.4111/icu.20240278

Internet

https://www.icurology.org/pdf/10.4111/icu.20240278

Similar Items